Bayer stock holds below 52-week high as legal date shifts
Published on 08/27/2026 at 07:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer (ISIN DE000BAY0017) stock traded at EUR 49.11 on the Xetra market as of August 26, 2026, placing the shares in the upper half of their recent trading range as investors digest both legal developments and the latest earnings picture. Per current market data, the price sits within a 52-week span from EUR 25.78 to EUR 53.92, underscoring how far the stock has recovered from last year’s lows.
Stock trades in upper range of 52-week band
Recent quote data from August 26, 2026 show Bayer shares changing hands at EUR 49.11 on the Frankfurt-based Xetra platform, with intraday trading between EUR 49.08 and EUR 49.93 that day. This market overview also reports that the current 52-week range of the stock extends from EUR 25.78 on the downside to EUR 53.92 on the upside, so the latest price is more than EUR 23 above the low and less than EUR 5 below the high.
On August 26, 2026, one market report highlighted that Bayer shares were up 0.5 percent in late Xetra trading at EUR 49.50, signaling a modest positive daily move. The same report put the late-session level EUR 0.39 above the previous close of EUR 49.11, underlining that the stock has been grinding higher but remains below its recent peak.
Glyphosate hearing delay shapes legal risk perception
Beyond day-to-day price action, the risk profile for Bayer continues to be influenced by litigation related to glyphosate-based herbicides. One detailed legal-focused commentary on August 27, 2026 explains that a key US hearing connected to a glyphosate settlement framework has been postponed to September 14, 2026. According to the piece, this date change has not derailed the stock’s constructive trend, since the shares continue to trade above important moving averages tracked by technical investors.
The same analysis notes that the current Bayer share price still sits 9 percent below a 52-week high of EUR 53.86, which implies that the market is pricing in progress but not a full resolution of the legal overhang. From EUR 49.00, a move back to EUR 53.86 would require an increase of EUR 4.86 per share, while the distance down to the 52-week low of EUR 25.78 is more than EUR 23, illustrating how much value has already been restored as the legal risks have been managed step by step.
Earnings recovery and valuation context
Investors now put the trading level into the context of Bayer’s recent financial results and outlook. Even without fresh quarterly data in the latest 24-hour news flow, the current 52-week low-high span combined with the late-August price indicates that the company has successfully recaptured a significant portion of the market capitalization lost at the trough in 2025. Historical price tables show that at the end of August 2025 the stock closed at EUR 28.35, which means that the current EUR 49.11 level is more than EUR 20 higher than that month-end value. This historical overview highlights a climb from the high-20s into the high-40s within one year.
That roughly EUR 20 recovery per share over 12 months equals a gain of more than 70 percent, and a separate trading commentary points out that Bayer’s share price performance over the last year has been strong enough to deliver a 74 percent gain over the period. The trading-oriented article also observes that the current price of EUR 49.62 quoted there stands 21 percent above the stock’s 200-day moving average, a metric that many chart watchers interpret as a sign of a sustained medium-term uptrend.
For valuation-focused investors, the combination of a roughly 70 to 74 percent 12-month price increase and a position still 9 percent below the 52-week high creates a nuanced picture. On one hand, the sizeable rebound suggests that a large part of the pessimism seen in 2025 has faded. On the other hand, the lag to the 52-week top signals that the market is still assigning a risk discount as the company navigates US legal procedures, executes its ongoing transformation program, and works to deliver growth in key segments such as crop science and pharmaceuticals.
Crop science portfolio and flagship herbicide
A central element of Bayer’s business model is its crop science division, which provides seeds, traits, and crop protection products to farmers worldwide. Within that division, glyphosate-based herbicides play a critical role in helping growers manage weeds efficiently in a wide range of crops. This product family has been at the heart of the US litigation that continues to shape investor sentiment, but it also generates substantial revenue and underpins Bayer’s integrated offering to agricultural customers.
Alongside glyphosate formulations, Bayer markets a broad portfolio of selective herbicides, fungicides, and insecticides, as well as digital farming solutions that support precision agriculture. These products are designed to boost yields and improve resource efficiency, which is strategically important as global demand for food remains high and climate variability challenges harvest stability. How successfully Bayer can balance the commercial strength of this portfolio with regulatory, environmental, and legal expectations will be a key driver of the stock’s long-term risk-reward profile.
Bayer stock levels as of late August 2026
As of the Xetra session on August 26, 2026, a consolidated market-data snapshot shows Bayer shares at EUR 49.11 with an intraday range between EUR 49.08 and EUR 49.93 and a 52-week range spanning EUR 25.78 to EUR 53.92. The same quote overview confirms that the stock is traded on the Frankfurt Stock Exchange’s Xetra platform under the ticker BAYN. While intraday volatility remains moderate, the position within the upper segment of the 52-week band and the meaningful recovery versus the end of August 2025 level highlight Bayer stock’s improved standing in equity markets heading into the September 14, 2026 glyphosate hearing.
Read more
Crop protection products support earnings power
Beyond the headline herbicide franchise, Bayer’s crop protection lineup includes a range of branded products that contribute to the company’s earnings power and strategic positioning. These offerings are typically supported by multi-year R&D investments and extensive regulatory dossiers, allowing the group to capture value across the lifecycle of its active ingredients. As farmers adopt integrated pest management strategies and seek resilient yield solutions, demand for innovative crop protection and seed technologies can help underpin Bayer’s top line and margins over time.
Shares consolidate gains below recent peak
In the equity market, Bayer stock is currently consolidating in the high-40s euro area on Xetra as of August 26, 2026, after climbing from the high-20s region a year earlier and trading within a 52-week interval of EUR 25.78 to EUR 53.92. For investors, the key question over the coming weeks will be how the September 14, 2026 glyphosate hearing and subsequent legal milestones interact with the company’s fundamental execution across crop science, pharmaceuticals, and consumer health to determine whether the shares can test or exceed the upper end of that range.
Fact box
Company: Bayer AG
ISIN: DE000BAY0017
Ticker: BAYN
Exchange: Xetra (Frankfurt Stock Exchange)
Price (as of August 26, 2026, 5:37 p.m. CET): EUR 49.11
Sector / Industry: Health care / Pharmaceuticals and crop science
